Mangalam Drugs & Organics Ltd (MANGALAM) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Mangalam Drugs & Organics Ltd on NSE and BSE, with an AI summary of each filing.
Intimation under Regulation 36(1)(b) of SEBI (LODR) Regulations, 2015 - Dispatch of Letter for Non- Email Cases
Others (Uncategorized) · 04 Nov 2026, 8:44 pm
Mangalam Drugs Dispatches AGM Notice and FY26 Annual Report Access Links Mangalam Drugs and Organics Ltd. has issued physical letters containing web-links to access its FY26 Annual Report and 53rd Annual General Meeting notice to shareholders without registered email addresses. The 53rd AGM is scheduled for 23rd Sep'26 at 3:00 PM IST via video conferencing. The record cut-off date was 16th Sep'26. Additionally, the company reminded physical security holders to complete mandatory KYC updates—including PAN, nomination, bank details, and specimen signatures—and advised dematerialisation pursuant to SEBI regulatory mandates.
Intimation for members consent received under Regulation 30 of SEBI (LODR), 2015 for appointment of Mr. Prabhakar Zavar as an Independent Director wef. September 15 2026 for term of 5 years, ....
Change in Management · 02 Nov 2026, 9:40 pm
Mangalam Drugs Shareholders Approve Appointment of Independent Director Prabhakar Raghunath Zavar Mangalam Drugs and Organics Limited announced that shareholders approved a special resolution via postal ballot for appointing Mr. Prabhakar Raghunath Zavar (DIN: 11940187), aged 78, as an Independent Director for a five-consecutive-year term. The remote e-voting concluded on 31st Oct'26, recording total valid votes of 5,714,609 across 109 members. The resolution passed with an overwhelming majority, securing 5,711,612 votes (99.9476%) in favor and 2,997 votes (0.0524%) against. Promoter and public institutional categories voted 100% in favor of the proposal.
To consider and approve the financial results for the period ended September 30, 2026 and other business matters
Intimation · 05 Nov 2026, 5:30 am
MANGALAM DRUGS AND ORGANICS LIMITED has informed the Exchange about Board Meeting to be held on 05-Nov-2026 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended September 2026 and Other business.
Intimation · 05 Nov 2026, 5:30 am
MANGALAM DRUGS AND ORGANICS LIMITED has informed the Exchange about Board Meeting to be held on 05-Nov-2026 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended September 2026 and Other business.
Intimation · 05 Nov 2026, 5:30 am
MANGALAM DRUGS AND ORGANICS LIMITED has informed the Exchange about Board Meeting to be held on 05-Nov-2026 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended September 2026 and Other business.
Intimation · 05 Nov 2026, 5:30 am
Mangalam Drugs & Organics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve The Unaudited Financial ....
Intimation · 05 Nov 2026, 5:30 am
Mangalam Drugs and Organics Schedules Board Meeting for Q2 Results Approval Mangalam Drugs and Organics Ltd announced that a meeting of its Board of Directors is scheduled for 5th Nov'26 to consider, approve, and take on record the un-audited standalone and consolidated financial results for the quarter ended 30th Sep'26. Additionally, the trading window for dealing in company securities, which has been closed for designated persons since 1st Oct'26, will remain closed until 48 hours after the declaration of the financial results.
Subsequent Intimation for Bank Default under Para A of Schedule III of Regulation 30 of SEBI (LODR), 2015.
Others (Uncategorized) · 16 Oct 2026, 8:34 pm
Mangalam Drugs Discloses Overdue Loan Defaults Totaling Rs 1,557.27 Lakhs Mangalam Drugs and Organics Limited reported continued defaults exceeding 30 days on cash credit facilities with Bank of Maharashtra and Bank of Baroda. As of 15th Oct'26, total overdue amounts reached Rs 1,557.27 lakhs, comprising Rs 951.19 lakhs due to Bank of Maharashtra (default start date: 17th Oct'25) and Rs 606.08 lakhs due to Bank of Baroda (default start date: 20th Oct'25). The company stated it is actively making arrangements to clear the outstanding dues.
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Others (Uncategorized) · 28 Sept 2026, 5:25 pm
Mangalam Drugs Confirms Non-Applicability of SEBI Large Corporate Framework Mangalam Drugs and Organics Limited confirmed to BSE and NSE on 28th Sep'26 that it does not fall under the Large Corporate category as on 31st Mar'26 pursuant to SEBI debt issuance circulars. The company reported outstanding borrowings of Rs 7.50 crore (Rs 749.76 lakhs) and a credit rating of CRISIL-D during the previous financial year. Consequently, mandatory debt security fund-raising requirements and associated non-compliance framework disclosures remain non-applicable.
Intimation pursuant to Regulation 30 of SEBI (LODR), 2015 for the term completion of M/s V.S. Somani and Co. , Chartered Accountants as Statutory Auditor in the 53rd AGM of the Company.
Change in Management · 24 Sept 2026, 11:52 pm
Intimation under Regulation 30 of SEBI (LODR), 2015, post shareholders approval for appointment of M/s S. N Nanda & Co, Chartered Accountants as Statutory Auditor for 5 years from conclusion ....
Change in Auditor · 24 Sept 2026, 11:50 pm
Intimation pursuant to Regulation 30 of SEBI (LODR), 2015 for the approval of shareholders in AGM regarding appointment of Statutory and Secretarial Auditor and Retirement of term of outgoing ....
Change in Management · 24 Sept 2026, 11:46 pm
Intimation under Regulation 44 of SEBI ( LODR), 2015 regarding voting results and combined scrutinizer report for 53rd Annual General Meeting of the Company.
Annual General Meeting · 24 Sept 2026, 11:24 pm
Intimation for the Proceedings of the 53rd Annual General Meeting of the Company held on Wednesday, 23/09/2026 , started at 3:00 pm and concluded at 4:00 pm through video conferencing under ....
Annual General Meeting · 24 Sept 2026, 12:41 am
Subsequent Disclosure under Regulation 30 Para A of Schedule III of LODR 2015 for the bank default of the Company
Others (Uncategorized) · 16 Sept 2026, 12:09 am
Mangalam Drugs Discloses Overdue Loan Defaults Totaling Rs 15.57 Crore Mangalam Drugs and Organics disclosed continuing loan defaults exceeding 30 days on its cash credit facilities with Bank of Maharashtra and Bank of Baroda. As of 14th Sep'26, total overdue amounts stood at Rs 1,557.27 lacs, comprising Rs 951.19 lacs owed to Bank of Maharashtra (default started 17th Oct'25) and Rs 606.08 lacs to Bank of Baroda (default started 20th Oct'25). The company stated it is actively making arrangements to pay the overdue amounts as soon as possible.
Disclosure under Regulation 30 of LODR, 2015 for the appointment of Mr. Prabhakar Raghunath Zavar (DIN: 11940187) as the Additional Independent Director ( Non- Executive) for term of 5 ....
Change in Management · 15 Sept 2026, 10:02 pm
Mangalam Drugs Appoints Prabhakar Raghunath Zavar as Independent Director Mangalam Drugs and Organics Limited's Board approved the appointment of Mr. Prabhakar Raghunath Zavar (DIN: 11940187) as an Additional Director (Independent Non-Executive Director) for a five-year term effective 15th Sep'26, subject to shareholder approval at the ensuing Extra-Ordinary General Meeting. Mr. Zavar brings over 38 years of experience in accounts, finance, taxation, and international trade. He is unrelated to any existing directors on the board.
Mangalam Drugs And Organics Limited has informed the Exchange regarding Outcome of Board Meeting held on September 15, 2026.
Outcome · 15 Sept 2026, 9:51 pm
Outcome of Board Meeting pursuant to Regulation 30 of LODR for appointment of Mr. Prabhakar Raghunath Zavar as the Additional Indepedent Director ( Non- Executive) for term of 5 years wef. ....
Outcome · 15 Sept 2026, 9:44 pm
Mangalam Drugs Appoints Prabhakar Raghunath Zavar as Independent Director Mangalam Drugs and Organics Limited approved the appointment of Mr. Prabhakar Raghunath Zavar (DIN: 11940187) as an Additional Director (Independent Non-Executive Director) for a five-year term effective 15th Sep'26, subject to shareholder approval at the upcoming EGM. Mr. Zavar brings over 38 years of professional expertise across accounts, finance, taxation, and international trade. He holds no familial relationships with any existing directors of the company.
Intimation of dispatch of Annual Report for 53rd Annual General Meeting for the financial year 2025-26 to be held on Wednesday, September 23rd, 2026 to the Shareholders of the Company.
Others (Uncategorized) · 31 Aug 2026, 11:29 pm
Annual Report of the Company, Notice convening 53rd Annual General Meeting for the financial year 2025-26 to be Held on Wednesday, September 23rd, 2026 and Intimation of Cut-off Date for ....
Annual General Meeting · 31 Aug 2026, 11:22 pm
Intimation of default under Para A sub- paragraph 6 Schedule III-subsequent default
Others (Uncategorized) · 17 Aug 2026, 10:09 pm
Mangalam Drugs Discloses Default on Bank Loan Obligations Mangalam Drugs and Organics Ltd disclosed a default on loan obligations to Bank of Maharashtra and Bank of Baroda for over 30 days. As of 16 Aug'26, the total overdue amount from cash credit facilities stands at ₹1,557.27 lacs (₹15.57 crore). The default on the ₹951.19 lac loan from Bank of Maharashtra began on 17 Oct'25, and the default on the ₹606.08 lac loan from Bank of Baroda began on 20 Oct'25. The company is making arrangements for repayment.
Appointment of Secretarial Auditor of the Company for term of 5 years from F.Y. 2026-27 to 2030-31 subject to approval of shareholders in ensuing 53rd AGM of the Company
Annual General Meeting · 12 Aug 2026, 11:30 pm
Appointment of Statutory Auditor for the period of 5 years subject to approval of sharehoders at ensuing 53rd Annual General meeting.
Change in Auditor · 12 Aug 2026, 11:15 pm
Declaration of Un-audited Financial results (Standalone & Consolidated) for the quarter ended 30th June, 2026
Financial Result · 12 Aug 2026, 11:07 pm
Mangalam Drugs Q1FY27 Results: Losses Narrow Sequentially Mangalam Drugs reported a Q1FY27 standalone net loss of ₹755.36 lakhs for the quarter ended 30 Jun'26, narrowing from a ₹1,306.04 lakh loss in Q4FY26 but widening from a ₹1,372.80 lakh loss YoY. Revenue from operations was flat YoY at ₹5,711.93 lakhs, down 15.1% QoQ. Total expenses decreased 20.4% QoQ to ₹6,389.19 lakhs. The board approved the appointment of new Secretarial and Statutory auditors, M/s L.N. Joshi & Co. and M/s S.N. Nanda & Co. respectively, for five-year terms.
Outcome of Board meeting held on 12th August, 2026 interalia for approval of Un-Audited Financial results (Standalone & Consolidated) for the quarter ended 30th June, 2026
Outcome · 12 Aug 2026, 10:46 pm
Mangalam Drugs: Q1FY27 Results, Auditor Appointments Approved by Board Mangalam Drugs reported a consolidated net loss of ₹7.64 Cr for Q1FY27, narrowing from a ₹13.80 Cr loss in Q1FY26. Revenue from operations was flat YoY at ₹57.12 Cr. The Board, in its meeting on 12 Aug'26, approved these results and also appointed new auditors. M/s L.N. Joshi & Co. are appointed as Secretarial Auditors and M/s S.N. Nanda & Co. as Statutory Auditors, both for five-year terms subject to shareholder approval at the upcoming 53rd AGM. The auditors issued an unmodified limited review report.